Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Foreign-Exchange Provisioning Masks Indian Pharma Health

This article was originally published in PharmAsia News

Executive Summary

Stock analysts see a rosy future for India's pharmaceutical companies that saw an overall 23 percent increase in net sales during the recent quarter. Analysts see an even better quarter following as long as the rupee does not fluctuate greatly with the U.S. dollar. The leading companies suffered a hit by having to provision for foreign-exchange losses, causing some of the firms to post losses within India for the quarter. Analysts also note Indian drug makers are expected to weather a global economic slowdown because drugs are considered essential products. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts